Iron chelating drugs.
作者信息
Kontoghiorghes G J
出版信息
Br Med J (Clin Res Ed). 1988 Jun 11;296(6637):1672-3. doi: 10.1136/bmj.296.6637.1672-c.
Abstract
摘要
相似文献
1
Iron chelating drugs.铁螯合剂药物。
Br Med J (Clin Res Ed). 1988 Jun 11;296(6637):1672-3. doi: 10.1136/bmj.296.6637.1672-c.
2
Oral iron chelating drugs: coming but not yet ready for clinical use.口服铁螯合剂药物：即将问世但尚未准备好用于临床。
Br Med J (Clin Res Ed). 1988 Apr 16;296(6629):1081-2. doi: 10.1136/bmj.296.6629.1081.
3
Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.非输血依赖型地中海贫血（NTDT）的铁螯合疗法：现状
Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):88-90. doi: 10.1016/j.bcmd.2013.08.006. Epub 2013 Sep 13.
4
An oral treatment for iron overload in thalassemia?
Hepatology. 1996 Feb;23(2):380-2. doi: 10.1002/hep.510230229.
5
Iron Chelation in Patients with Transfusion Dependent Thalassemia: An Insight on Response to Deferasirox.输血依赖型地中海贫血患者的铁螯合：对去铁斯若反应的见解
J Coll Physicians Surg Pak. 2015 Jul;25(7):553-4.
6
Do we need more iron-chelating drugs?
Lancet. 2003 Aug 9;362(9382):495-6. doi: 10.1016/S0140-6736(03)14085-8.
7
[Principles of treatment with iron chelates].[铁螯合剂的治疗原则]
Gematol Transfuziol. 1990 Mar;35(3):13-5.
8
[Roles of iron overload and chelating treatment in Yersinia infectious complicated by major thalassemia].[铁过载及螯合治疗在重型地中海贫血合并耶尔森菌感染中的作用]
Presse Med. 1987 Oct 3;16(32):1574-6.
9
Report on the proceedings of the 15th International Conference on Oral Chelation (ICOC) in the Treatment of Thalassemia and Other Diseases at Taichung, Taiwan, April 22-26, 2005.
Hemoglobin. 2006;30(1):63-8. doi: 10.1080/03630260500454709.
10
Deferasirox in thalassemia patients with end-stage renal disease.地拉罗司用于终末期肾病地中海贫血患者。
Am J Hematol. 2016 Oct;91(10):E456-7. doi: 10.1002/ajh.24457. Epub 2016 Jul 14.
引用本文的文献
1
Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects.地拉罗司和铁-麦芽酚：从发现到药物设计、研发、临床应用及未来前景的四十年。
Int J Mol Sci. 2023 Mar 4;24(5):4970. doi: 10.3390/ijms24054970.
本文引用的文献
1
Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits.
Br J Haematol. 1986 Apr;62(4):607-13. doi: 10.1111/j.1365-2141.1986.tb04082.x.
2
Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.
Mol Pharmacol. 1986 Dec;30(6):670-3.
3
Dose response studies using desferrioxamine and orally active chelators in a mouse model.在小鼠模型中使用去铁胺和口服活性螯合剂的剂量反应研究。
Scand J Haematol. 1986 Jul;37(1):63-70. doi: 10.1111/j.1600-0609.1986.tb01773.x.
4
Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.在正常和铁负荷大鼠中使用去铁胺和潜在的口服螯合剂1,2-二甲基-3-羟基吡啶-4-酮进行的铁螯合研究。
J Clin Pathol. 1987 Apr;40(4):404-8. doi: 10.1136/jcp.40.4.404.
5
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.口服螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮对β地中海贫血中铁的有效螯合作用
Br Med J (Clin Res Ed). 1987 Dec 12;295(6612):1509-12. doi: 10.1136/bmj.295.6612.1509.
6
1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮，一种用于治疗铁过载的口服活性螯合剂。
Lancet. 1987 Jun 6;1(8545):1294-5. doi: 10.1016/s0140-6736(87)90545-9.
Zotero 插件